Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2.TR2.4-1BB CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HER2.TR2.4-1BB CAR-T cells (also known as CAR.HER2.TR2.4-1BB T cells) are genetically engineered autologous T cells developed by researchers at the Baylor College of Medicine. These CAR-T cells are designed to target HER2-expressing solid tumors, such as HER2-positive breast cancer, while simultaneously overcoming the immunosuppressive tumor microenvironment (TME). They co-express a HER2-specific chimeric antigen receptor (CAR) and a novel chimeric co-stimulatory receptor, TR2.4-1BB. The TR2.4-1BB receptor consists of a single-chain variable fragment (scFv) derived from a monoclonal antibody targeting tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2/TR2), which is highly expressed on myeloid-derived suppressor cells (MDSCs) in the TME, fused to a 4-1BB (CD137) costimulatory endodomain. Upon binding to TR2 on MDSCs, the TR2.4-1BB receptor induces apoptosis in the suppressive MDSCs while delivering a costimulatory signal to the CAR-T cells, enhancing their persistence, proliferation, and anti-tumor efficacy.
- Other names
- CAR.HER2.TR2.4-1BB CAR-T cellsCAR.HER2.TR2.4-1BB T cellsHER2.TR2.4-1BB CARTsHER-2.TR2.4-1BB CARTsHER 2.TR2.4-1BB CARTs
02
Targets
TNFRSF10B (DR5)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2.TR2.4-1BB CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2.TR2.4-1BB CAR-T cells.